Meticulous Research®—a leading global market research company, published a research report titled, ‘Cancer Immunotherapy Market by Type (Monoclonal Antibodies [Naked, Conjugated], Cytokines, Checkpoint Inhibitors [CTLA4, PD-L1], Vaccines, Cell Therapies) Cancer Type (Lung, Breast, Colorectal, Prostate, Prostate, Multiple Melanoma) - Global Forecast to 2030.’

According to this latest publication from Meticulous Research®, the global cancer immunotherapy market is projected to reach $ 267.2 billion by 2030, at a CAGR of 11.6% during the forecast period 2023–2030. The growth of the cancer immunotherapy market is attributed to the rising cancer incidence, growing adoption of immunotherapy over other treatment options, increasing collaborations among market players to develop new cancer immunotherapies, and high spending on cancer care. Further, initiatives to boost cancer screening, growth prospects in emerging economies, and integration of bioinformatic tools to boost cancer research are creating opportunities for the growth of this market.

Cancer Immunotherapy Market: Future Outlook

The global cancer immunotherapy market study is segmented by type (monoclonal antibodies [naked monoclonal antibodies, conjugated monoclonal antibodies, bispecific monoclonal antibodies], immunomodulators [cytokines, oncolytic virus, immunomodulatory drugs, checkpoint inhibitors {cytotoxic T-lymphocyte-associated protein, programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1)}, vaccines, cell therapies]), cancer type (lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, multiple myeloma, bladder cancer, liver cancer, lymphoma, and other cancer types), and geography. The study also evaluates industry competitors and analyzes their market shares at the global and regional levels.

Based on type, in 2023, the monoclonal antibodies segment is expected to account for the largest share of the global cancer immunotherapy market. Monoclonal antibodies directly attack cancer cells, trigger an immune system response, destroy cancer's outer membrane, and block cancer cells' cell growth. Additionally, monoclonal antibodies have fewer side effects over the alternative treatments, making them preferable over other treatments.

Based on cancer type, in 2023, the lung cancer segment is expected to account for the largest share of the global cancer immunotherapy market. Immunotherapy alone or in combination with conventional treatments has proven to significantly improve outcomes for patients affected with lung cancer. Thus, the high prevalence of lung cancer and the high adoption of immunotherapies for lung cancer are contributing to the large market share of this segment.

This research report analyzes major geographies and provides a comprehensive analysis of North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and the Middle East & Africa.

Based on geography, in 2023, North America is expected to account for the largest share of the cancer immunotherapy market, followed by Europe and Asia-Pacific. In 2023, the U.S. is expected to account for the largest share of the cancer immunotherapy market in North America. The large share of this market is primarily driven by high healthcare expenditure for cancer, highly developed healthcare infrastructure, the presence of key cancer immunotherapy developing companies such as Johnson & Johnson (U.S.) and Merck & Co., Inc. (U.S.), and government programs supporting early cancer screening.

Key Players:

The key players operating in the global cancer immunotherapy market are AstraZeneca PLC (U.K), Amgen Inc.(U.S.), Bristol Myers Squibb Company (U.S.), Eli Lilly and Company (U.S.), Johnson & Johnson (U.S.), Merck & Co., Inc. (U.S.), Novartis AG (Switzerland), Pfizer Inc.(U.S.), F. Hoffmann-La Roche Ltd (Switzerland), and CytomX Therapeutics, Inc. (U.S.).

Download Sample PDF Copy Here : https://www.meticulousresearch.com/download-sample-report/cp_id=4690

Key questions answered in the report-

1 Which are the high-growth market segments in terms of type, cancer type, and geography?
2 What was the historical market for cancer immunotherapy across the globe?
3 What are the market forecasts and estimates for the period 2023–2030?
4 What are the major drivers, restraints, opportunities, and challenges in the global cancer immunotherapy market?
5 Who are the major players in the global cancer immunotherapy market?
6 How is the competitive landscape, and who are the market leaders in the global cancer immunotherapy market?
7 What are the recent developments in the cancer immunotherapy market?
8 What are the different strategies adopted by the major players in the cancer immunotherapy market?
9 What are the geographic trends and high growth regions/countries?

Contact Us:
Meticulous Research®
Email- [email protected]
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research